Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T82051 | ||||
| Target Name | P53 messenger RNA (TP53 mRNA) | ||||
| Synonyms | Tumor suppressor p53 (mRNA); Phosphoprotein p53 (mRNA); P53 (mRNA); Antigen NY-CO-13 (mRNA) | ||||
| Target Type | Clinical trial | ||||
| Gene Name | TP53 | ||||
| Biochemical Class | mRNA target | ||||
| UniProt ID | P53_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Acute myelocytic leukemia | ||||
| Example drug | Cenersen | Phase 2 | [1], [2], [3], [4] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.3 Z-score: 0.59 P-value: 7.90E-07 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8270). | ||||
| REF 2 | Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. | ||||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 4 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.